Kristof Van Kolen

Beerse, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 27 publications

Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease.

Phase 1 Studies of the Anti-Tau Monoclonal Antibody JNJ-63733657 in Healthy Participants and Participants with Alzheimer's Disease.

Journal: The journal of prevention of Alzheimer's disease

Published: November 19, 2024

NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

NLRP3 inflammasome activation and pyroptosis are dispensable for tau pathology.

Journal: Frontiers in aging neuroscience

Published: July 03, 2024

Behavioral and Neuropathological Phenotyping of the Tau58/2 and Tau58/4 Transgenic Mouse Models for FTDP-17.

Behavioral and Neuropathological Phenotyping of the Tau58/2 and Tau58/4 Transgenic Mouse Models for FTDP-17.

Journal: Life (Basel, Switzerland)

Published: July 24, 2023

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies.

Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies.

Journal: Molecular therapy. Methods & clinical development

Published: June 29, 2023

Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid.

Development and Characterization of Mouse-Specific Anti-Tau Monoclonal Antibodies: Relevance for Analysis of Murine Tau in Cerebrospinal Fluid.

Journal: Journal of Alzheimer's disease : JAD

Published: March 27, 2023

Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.

Enhanced delivery of antibodies across the blood-brain barrier via TEMs with inherent receptor-mediated phagocytosis.

Journal: Med (New York, N.Y.)

Published: October 28, 2021

Development and validation of a high-sensitivity assay for measuring p217+tau in plasma.

Development and validation of a high-sensitivity assay for measuring p217+tau in plasma.

Journal: Alzheimer's & dementia (Amsterdam, Netherlands)

Published: March 26, 2021

Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody.

Discovery and Functional Characterization of hPT3, a Humanized Anti-Phospho Tau Selective Monoclonal Antibody.

Journal: Journal of Alzheimer's disease : JAD

Published: September 07, 2020

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid.

Development and Validation of a High Sensitivity Assay for Measuring p217 + tau in Cerebrospinal Fluid.

Journal: Journal of Alzheimer's disease : JAD

Published: August 25, 2020

Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils.

Comparison of size distribution and (Pro249-Ser258) epitope exposure in in vitro and in vivo derived Tau fibrils.

Journal: BMC molecular and cell biology

Published: April 08, 2020

Progressive tau aggregation does not alter functional brain network connectivity in seeded hTau.P301L mice.

Progressive tau aggregation does not alter functional brain network connectivity in seeded hTau.P301L mice.

Journal: Neurobiology of disease

Published: January 06, 2020

Regional vulnerability and spreading of hyperphosphorylated tau in seeded mouse brain.

Regional vulnerability and spreading of hyperphosphorylated tau in seeded mouse brain.

Journal: Neurobiology of disease

Published: October 29, 2018

Showing 1-12 of 27

Last Updated: 09/26/2026